

General Information

Name: Prof. Dr. med. Lüder Hinrich Meyer
Date of Birth: 22.04.1968
Gender: Male
Address: Department of Pediatrics and Adolescent Medicine, Ulm University
Eythstrasse 24, 89075 Ulm, Germany
Phone: +49 731 500 57254
E-Mail: lueder-hinrich.meyer@uniklinik-ulm.de
Current Position: Group Leader, Senior Physician

Academic Education

1996-1998 Scholarship, Graduate School 'Molecular and cellular mechanisms of pathogenesis', Mainz University
1996 Medical Licensing Examination
1994-1996 University of Lübeck Medical School
1993-1994 University of Bergen (Norway) Medical School
1989-1993 University of Lübeck Medical School

Academic Degrees

2018 Professor (apl.), Ulm University
2013 Postdoctoral Thesis (*Habilitation*), Pediatrics, Ulm University, Mentor: Prof. K.-M. Debatin
2000 Doctoral Thesis (*Promotion*), Medicine, Mainz University, Mentor: Prof. S. Rose-John

Professional Experience

2010 Board Certification: Pediatric Oncology and Hematology
2007 Group Leader, Research Laboratory, Department of Pediatrics and Adolescent Medicine, Ulm University Hospital
2006 Senior Physician Oncology/Hematology, Department of Pediatrics and Adolescent Medicine, Ulm University Hospital
2005 Board Certification in Pediatrics
2002-2005 Clinical Fellow, Department of Pediatrics and Adolescent Medicine, Ulm University Hospital
2001-2002 Post-doctoral Fellow, Research Laboratory, Department of Pediatrics and Adolescent Medicine, Ulm University Hospital
2000-2001 Clinical Fellow, Department of Pediatrics and Adolescent Medicine, Ulm University Hospital
1998-2000 Clinical fellow, University Children's Hospital, Mainz University

Miscellaneous

Awards, Honors, Positions:

2011 Kind Philipp Award, Society for Pediatric Oncology and Hematology
2007 Lina Marguerite Siebert Forschungspreis, Children's Cancer Research Foundation
2006 Research Fellowship 2007 - 2008, European Hematology Association
2006 Research Prize, Society for Pediatric Oncology and Hematology

Publications

1. Seyfried F, Demir S, Hörl RL, Stirnweiß FU, Ryan J, Scheffold A, Villalobos-Ortiz M, Boldrin E, Zinngrebe J, Enzenmüller S, Jenni S, Tsai YC, Bornhauser B, Fürstberger A, Kraus JM, Kestler HA, Bourquin JP, Stilgenbauer S, Letai A, Debatin KM, Meyer LH. Prediction of venetoclax activity in precursor B-ALL by functional assessment of apoptosis signaling. **Cell Death Dis.** 2019;10(8):571.
2. Demir S, Boldrin E, Sun Q, Hampp S, Tausch E, Eckert C, Ebinger M, Handgretinger R, Te Kronnie G, Wiesmüller L, Stilgenbauer S, Selivaova G, Debatin KM, Meyer LH. Therapeutic targeting of mutant p53 in pediatric acute lymphoblastic leukemia. **Haematologica.** 2019 May 9. [Epub ahead of print]
3. Wang F, Demir S, Gehringer F, Osswald CD, Seyfried F, Enzenmüller S, Eckhoff SM, Maier T, Holzmann K, Debatin KM, Wirth T*, Meyer LH*, Ushmorov A*. Tight regulation of FOXO1 is essential for maintenance of B-cell precursor acute lymphoblastic leukemia. **Blood.** 2018;131(26):2929-42. *Equal contribution
4. Alsadeq A, Lenk L, Vadakumchery A, Cousins A, Vokuhl C, Khadour A, Vogiatzi F, Seyfried F, Meyer LH, Cario G, Hobeika E, Debatin KM, Halsey C, Schrappe M, Schewe DM, Jumaa H. IL7R is associated with CNS infiltration and relapse in pediatric B-cell precursor acute lymphoblastic leukemia. **Blood.** 2018;132(15):1614-17.
5. Trentin L, Queudeville M, Eckhoff SM, Hasan MN, Münch V, Boldrin E, Seyfried F, Enzenmüller S, Debatin KM*, Meyer LH*. Leukemia reconstitution in vivo is driven by cells in early cell cycle and low metabolic state. **Haematologica.** 2018;103(6):1008-17. *Equal contribution
6. Münch V, Trentin L, Herzig J, Demir S, Seyfried F, Kraus JM, Kestler HA, Köhler R, Barth TFE, Te Kronnie G, Debatin KM*, Meyer LH*. Central nervous system involvement in acute lymphoblastic leukemia is mediated by vascular endothelial growth factor. **Blood.** 2017;130(5):643-54. *Equal contribution
7. Köhrer S, Havranek O, Seyfried F, Hurtz C, Coffey GP, Kim E, Ten Hacken E, Jäger U, Vanura K, O'Brien S, Thomas D, Kantarjian H, Ghosh D, Wang Z, Zhang M, Ma W, Jumaa H, Debatin KM, Müschen M, Meyer LH, Davis R, Burger J. Pre-BCR signaling in precursor B-cell acute lymphoblastic leukemia regulates PI3K/AKT, FOXO1 and MYC, and can be targeted by SYK inhibition. **Leukemia.** 2016;30(6):1246-54.
8. Schirmer M, Trentin L, Queudeville M, Seyfried F, Demir S, Tausch E, Stilgenbauer S, Eckhoff SM, Meyer LH*, Debatin KM*. Intrinsic and chemo-sensitizing activity of SMAC-mimetics on high-risk childhood acute lymphoblastic leukemia. **Cell Death Dis.** 2016;14;7:e2052. *Equal contribution
9. Hasan MN, Queudeville M, Trentin L, Eckhoff SM, Bronzini I, Palmi C, Barth T, Cazzaniga G, Te Kronnie G, Debatin KM, Meyer LH. Targeting of hyperactivated mTOR signaling in high-risk acute lymphoblastic leukemia in a pre-clinical model. **Oncotarget.** 2015;6(3):1382-95.
10. Meyer LH, Eckhoff SM, Queudeville M, Kraus JM, Giordan M, Stursberg J, Zangrando A, Vendramini E, Moricke A, Zimmermann M, Schrauder A, Lahr G, Holzmann K, Schrappe M, Basso G, Stahnke K, Kestler HA, Te Kronnie G, Debatin KM. Early Relapse in ALL Is Identified by Time to Leukemia in NOD/SCID Mice and Is Characterized by a Gene Signature Involving Survival Pathways. **Cancer Cell.** 2011;19(2):206-17.